Welcome to the eCancerTrials.com National Cancer Clinical Trials Database. When you or a loved one are diagnosed with cancer, knowing every treatment option available is your first step in receiving the most complete care. Your treatment plan may include choosing to participate in a cancer clinical trial. Clinical trials in cancer are research studies designed to evaluate new cancer treatment, management, and prevention options. Clinical trials conducted with cancer patients evaluate the safety and effectiveness of new or modified cancer treatment strategies. New anticancer drugs, unique approaches to surgery and radiation therapy are used as well as various combinations of cancer treatments.

Many medical professionals encourage those diagnosed with cancer to at least consider participating in a clinical trial in addition to other treatment options. Furthermore, many treatment options for cancer patients are only available through clinical trials, making participation in a trial the only way to access certain therapies. So if you are not evaluating potential cancer treatments accessible through the clinical trials process alongside current standard therapies, you're not weighing all of your available options.

Although there is currently no single, comprehensive source of available clinical trials, eCancerTrials.com’s provides information on more than 2,000 clinical trials being conducted by leading cancer researchers from all 50 states. These clinical trials evaluate novel treatment approaches and new cancer drugs in all major cancer types, including breast cancer, colon cancer, prostate cancer, lung cancer, lymphoma, leukemia, and many others.

eCancerTrials.com is a free and confidential cancer clinical trials matching and referral service. This resource is provided to cancer patients and their caregivers by leading cancer information specialists at CancerConsultants.com. Interested patients and their advocates may use this resource to:

• Search—free of charge—for clinical trials applicable to your situation.
• Search without sharing personal information until you find a trial that is appropriate. At this point you can directly call or e-mail the cancer clinic or center conducting the trial. In this manner your privacy is respected and ensured.
• eCancerTrials.com provides interested patients and their family members with additional services to help locate appropriate clinical trials.

Use the search engine below to look for clinical trials, or learn more about clinical trials.

Search by cancer type:

Select a cancer type --------------------------------- Acute Lymphoid Leukemia Acute Myeloid Leukemia Anal Cancer Any Cancer Any Cancer Type Bladder Cancer Blood Disorders Bone Metastasis Brain/Central Nervous System Cancer Breast Cancer Cervical Cancer Chronic Lymphocytic Leukemia Chronic Myeloid Leukemia Colorectal Cancer Esophageal Cancer Gastric Cancer Germ Cell Cancer Head & Neck Cancers High Risk Prostate Cancer Hodgkin's Lymphoma Liver Cancer Lymphoma Malignant Melanoma Malignant Mesothelioma Merkel Cell Cancer Multiple Myeloma Myelodysplastic Syndromes Neuroblastoma Non Small Cell Lung Cancer Non-Hodgkin's Lymphoma - High Grade Non-Hodgkin's Lymphoma - Intermediate Grade Non-Hodgkin's Lymphoma - Low Grade Non-Hodgkin's Lymphoma - Mantle Cell Osteosarcoma Other Ovarian Cancer Pancreatic Cancer Prostate Cancer Renal Cell (Kidney) Cancer Retinoblastoma Rhabdomyosarcoma Sarcoma Skin Cancer Small Cell Lung Cancer Soft Tissue Sarcoma Solid Tumors Supportive Care (Side Effects) Testicular Cancer-Non-Seminoma Testicular Cancer-Seminoma Thymic Thyroid Cancer Unknown Primary Uterine (Endometrial) Cancer Vaginal Cancer Wilm's Tumor  

Filter by:

All cancer stages --------------------------------- Screening & Prevention Carcinoma in Situ Stage 1 Stage 2 Stage 3 Inflammatory Stage 4 Recurrent/Refractory Advanced Stage 0 Stage 0 Stage I Stage IIA Stage IIB Early Stage All States ------------------------------- Northeast Region Southeast Region Midwest Region Northwest Region Southwest Region ------------------------------- Alabama Alaska Arizona Arkansas California Colorado Connecticut Delaware District of Columbia Florida Georgia Hawaii Idaho Illinois Indiana Iowa Kansas Kentucy Louisiana Maine Maryland Massachusetts Michigan Minnesota Mississippi Missouri Montana Nebraska Nevada New Hampshire New Jersey New Mexico New York North Carolina North Dakota Ohio Oklahoma Oregon Pennsylvania Rhode Island South Carolina South Dakota Tennessee Texas Utah Vermont Virginia Washington West Virginia Wisconsin Wyoming

Displaying clinical trials in "Breast Cancer" in "All cancer stages" in "All States":

Protocol No.	Title
W-1-07	A Phase III Randomized Study of Adjuvant Combination Chemotherapy and Hormonal Therapy versus Adjuvant Hormonal Therapy Alone in Women with Previously Resected Axillary Node-Negative Breast Cancer with Various Levels of Risk for Recurrance.
CTSU/ANZ0701	(Co-SOFT) Investigating Cognitive Function for Patients Participating in the SOFT Trial in Selected Centers
BrUOG	A Phase II Study of Adjuvant Gemcitabine/ Capecitabine/Bevacizumab for Patients Treated Neoadjuvantly for Early Stage Breast Cancer with High Risk for Relapse.
BCIRG006	A MULTICENTER, PHASE III RANDOMIZED TRIAL COMPARING DOXORUBICIN AND CYCLOPHOSPHAMIDE FOLLOWED BY DOCETAXEL (AC->T) WITH DOXORUBICIN AND CYCLOPHOSPHAMIDE FOLLOWED BY DOCETAXEL AND TRASTUZUMAB (AC->TH) AND WITH DOCETAXEL, PLATINUM SALT AND TRASTUZUMAB (TCH) IN THE ADJUVANT TREATMENT OF NODE POSITIVE AND HIGH RISK NODE NEGATIVE PATIENTS WITH OPERABLE BREAST CANCER CONTAINING THE HER2NEU ALTERATION.
BCIRG007	A Multicenter Phase III Randomized Trial Comparing Docetaxel (Taxotere®) and Trastuzumab (Herceptin®) with Docetaxel (Taxotere®), Platinum Salt (Cisplatin or Carboplatin) and Trastuzumab (Herceptin®) as First Line Chemotherapy for Patients With Advanced Breast Cancer Containing the HER2 Gene Amplification.
P-2	Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer
H2251n	Clinical Outcomes in Patients with HER2 Gene-Amplified Metastatic Breast Cancer Treated with First-Line Herceptin in Combination with a Taxane: A PHASE IV, Prospective, Community-Based Study
ECOGE5103	A Double-Blind Phase III Trial of Doxorubicin and Cyclophosphamide followed by Paclitaxel with Bevacizumab or Placebo in Patients with Lymph Node Positive and High Risk Lymph Node Negative Breast Cancer
INST0716C/MDA	Inflammatory Breast Cancer (IBC) Research Program
INST0711C	Efficacy of Using Isosulfan Blue for Sentinel Node Biopsy in Morbidly Obese Women
Acosog1071	A Phase II Study Evaluating the Role of Sentinel Lymph Node Surgery and Axillary Lymph Node Dissection Following Preoperative Chemotherapy in Women with Node Positive Breast Cancer (T1-4, N1-2, M0) at Initial Diagnosis
REFMAL30-BR	A PHASE I, OPEN-LABEL, MULTI-DOSE, DOSE-ESCALATION STUDY OF GW572016 IN PATIENTS WITH SOLID TUMORS-BR
ACOSOGZ1031	A Randomized Phase III Trial Comparing 16 to 18 Weeks of Neoadjuvant Exemestane (25 mg daily), Letrozole (2.5 mg), or Anastrozole (1 mg) in Postmenopausal Women with Clinical Stage II and III Estrogen Receptor Positive Breast Cancer (ACOSOG Z1031)
E7389-G000-211	A Phase II Open Label, Single-Arm Study of E7389 in Patients with Locally Advanced or Metastatic Breast Cancer, Previously Treated with Anthracycline, Taxane, and Capecitabine Therapy, Refractory to the Last Prior Therapy for Their Disease
REFMAL39	A Phase I, Open-Label, Dose-Escalation Study of SB-715992 Administered Weekly for Three Consecutive Weeks of 28-Day Cycle in Patients with Solid Tumors
CAL-03	A PHASE I-II, 24-WEEK MULTICENTER, DOUBLE-BLIND RANDOMIZED, DOSE-RANGING STUDY TO EVALUATE THE SAFETY AND EFFICACY OF HUMANIZED MONOCLONAL ANTIBODY TO PTHrP VERSUS ZOLEDRONIC ACID IN PATIENTS WITH BREAST CANCER METASTATIC TO BONE
EGF20002	An Open-Label, Multicenter, Single Arm Phase II Study of Oral GW572016 as Single Agent Therapy in Subjects with Advanced or Metastatic Breast Cancer Who Have Progressed While Receiving Herceptin¨ Containing Regimens
NSABPB-42	NSABP B-42: A clinical trial to determine the efficacy of five years of letrozole compared to placebo in patients completing five years of hormonal therapy consisting of an aromatase inhibitor(AI) or tamoxifen followed by an AI in prolonging Disease-Free survival in postmenopausal women with hormone receptor positive breast cancer
USO05090	A Phase III, multicenter, randomized, placebo-controlled trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy regimens in subjects with previously treated metastatic breast cancer.
W-4-05	A Randomized Phase II Trial of Three Doses of Perifosine in Combination with Trastuzumab
M-1-06	Osteopontin as a Biomarker for Breast Cancer.
A6181094	A Phase 3 Study of SU011248 in Combination With Paclitaxel Versus Bevacizumab with Paclitaxel in the First-Line Advanced Disease Setting in Patients Having Breast Cancer.
PACCT-1/TAILORx	Program for the Assessment of Clinical Cancer Tests (PACCT-1):Trial Assigning IndividuaLized Options for Treatment: The TAILORx Trial
W-1-09(ECOG5103)	A Double Blind Phase III Trial of Dose Dense Doxorubicin and Cyclophosphamide Followed by Paclitaxel with Bevacizumab of Placebo in Patients with Lymph Node Positive and High Risk Lymph Node Negative Breast Cancer.
369901	Observational Cohort Study: Chemotherapy Decisions and Outcomes in Women age 65 or older with Operable, Newly Diagnosed Breast Cancer.
W-4-04	A Phase III Randomized Study of Exemestane versus Placebo in Postmenopausal Women at Increased Risk of Developing Breast Cancer.
W-2-07	A Double-Blind, Randomized Phase 2b Study of Sorafenib Compared to Placebo when Administered in Combination with Chemotherapy for Patients with Locally Advanced or Metastatic Breast Cancer that has Progressed During or After Bevacizumab Therapy.
0517	Randomized Phase III Trial to Evaluate Radiopharmaceuticals and Zoledronic Acid in the Palliation of Osteoblastic Metastases from Lung, Breast, and Prostate Cancer
3144A2-3004-WW	A Randomized Double-Blind Placebo-Controlled Trial of Neratinib (HKI-272) after Trastuzumab in Women with Early-Stage HER-2/neu Overexpressed/Amplified Breast Cancer.
ECOGPACCT-1	ECOG PACCT-1: Program for the Assessment of Clinical Cancer Tests (PACCT-1) Trial Assigning Individualized Options for Treatment. The TAILORx TrialCOG
SWOGS0300	A Randomized Placebo-Controlled Biomarker modulation Trial Using Celecoxib in Premenopausal Women at High Risk for Breast Cancer is now open for enrollment at UNM.
E5103	A Double-Blind Phase III Trial of Doxorubicin and Cyclophosphamide Followed by Paclitaxel with Bevacizumab or Placebo in Patinents with Lymph Node Positive and High Risk Lymph Node Negative Breast Cancer.
Z1041	A Randomized Phase III Trial Compaing a Neoadjuvant Regimen of FEC-75 Followed By Plus Trastuzumab with a Neoadjuvant Regimen of Paclitaxel Plus Trastuzumab Followed by FEC-75 Plus Trastuzumab in Patients with Palpable and Operable Breast Cancer.
W-3-06	A Phase II study of Weekly Dose-Dense Nanoparticle Paclitaxel (ABI-007) Carboplatin with Herceptin as First-Line Therapy of Advanced HER-2 Positive Breast Cancer.
W-4-06	A Randomized, Double-blind, Multicenter, Placebo-controlled Study of Adjuvant Lapatinib in Women with Early-Stage ErbB2 Overexpressing Breast Cancer.
CALGB70301	: Quality of Life, Employment & Informal Care Cost Analysis in Women Receiving Adjuvant Chemotherapy for Breast Cancer with 0-3 Positive Axillary Lymph Nodes.
EGF19060	An Open-Label, Phase 1b Roll-over Study to Assess the Long-Term Safety Profile of Lapatinib in Cancer Patients is now open to accrual.
SWOGS0715	SWOG S0715: A Randomized Placebo-controlled Trial of Acetyl-L-Carnitine (ALC) For the Prevention of Taxane Induced Neuropathy, Phase III
06-166	Phase II, multicenter, open-label, clinical trial of Trabectedin (Yondelis?) in Metastatic Breast Cancer Patients with triple negative profile (ER-, PR-, HER2-), HER2 overexpressing tumors and BRCA1 or BRCA2 mutation carriers.
110557	An Open-Label, Two-Part, Single Sequence Study to Examine the Effects of Lapatinib on the Pharmacokinetics of Orally Administered Digoxin in Subjects with Metastatic ErbB2 Positive Breast Cancer
USON06106	A Phase II Randomized Trial of Weekly and Every 3-week-Ixabepilone in Metastatic Breast Cancer (MBC) Patients
S0307	Phase III Trial of Bisphosphonates as Adjuvant Therapy for Primary Breast Cancer
LPT111110	A Phase II, Single Arm, Multi-Center Study Evaluating the Combination of Vineorelbine and Lapatnib in Women with ErbB2 Overexpressing Metastatic Breast Cancer
08-065	A Phase II, Single-arm, Open-label Study OF TRASTUZUMAB-MCC-DM1 Administered Intravenously To Patients with HER2-POSITIVE Metastatic Breast Cancer
BrUOG-BR-213	A Phase II Study of Adjuvant Gemcitabine/Capecitabine and Avastin for Patients Treated Neoadjuvantly for Early Stage Breast Cancer with High Risk for Relapse
USON07132	A Phase III Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women with Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
TDM4370g	GENENTECH TDM 4370g A RANDOMIZED, MULTICENTER, PHASE III OPEN-LABEL STUDY OF THE EFFICACY AND SAFETY OF TRASTUZUMAB-MCC-DM1 VS. CAPECITABINE + LAPATINIB IN PATIENTS WITH HER2-POSITIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER WHO HAVE RECEIVED PRIOR TRASTUZUMAB-BASED THERAPY
NSABPB-43	A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy
CALGB40502	A Randomized Phase III Trial of Weekly Paclitaxel Compared to Weekly Nanoparticle Albumin Bound Nab-Paclitaxel or Ixabepilone Combined with Bevacizumab as First-Line Therapy for Locally Recurrent or Metastatic Breast Cancer.
E7070	An Open Label Phase II Study of E7070 in Metastatic Breast Cancer Patients Previously Treated with an Anthracycline, a Taxane and Capecitabine (or Fluoropyrimidine)
CALGB40101	Cyclophosphamide and Doxorubicin (CA x 4 cycles) versus Paclitaxel (4 cycles) as Adjuvant Therapy for Breast Cancer in Women with 0-3 Positive Axillary Lymph Nodes: A Phase III Randomized Study.
BRE43	Phase II Randomized Crossover Study of Doxorubicin HCl Liposome Injection (DOXIL) versus Weekly Docetaxel (Taxotere) in Patients in First Relapse Metastatic Breast Cancer.
BRE44	Phase II Trial of Weekly Gemcitabine And Herceptin In The Treatment of Patients with Her-2 Overexpressing Metastatic Breast Cancer.
BRE41	A RANDOMIZED MULTICENTER TRIAL COMPARING WEEKLY DOCETAXEL AND CMF (CYCLOPHOSPHAMIDE, METHOTREXATE, 5-FLOUROURACIL) IN THE ADJUVANT TREATMENT OF WOMEN WITH HIGH-RISK BREAST CANCER WHO ARE OVER 65 YEARS OLD OR ARE NOT CANDIDATES FOR ANTHRACYCLINE-BASED ADJUVANT THERAPY
BRE51	PHASE II TRIAL OF INDUCTION CHEMOTHERAPY WITH WEEKLY GEMCITABINE, AND EPIRUBICIN, DOCETAXEL AS PRIMARY TREATMENT OF LOCALLY ADVANCED OR INFLAMMATORY BREAST CANCER PATIENTS
SWOGS0916	SWOG S0916: A Phase II, Window Trial of the Anti-CCR2 Antibody MLN1202 (NSC-751448) in Patients with Bone Metastases
TAILORx	A Cancer Research Trial Assigning Individualized Options for Treatment
REFMAL31	A STUDY TO DETERMINE THE BIOEQUIVALENCE OF AN ORAL FORMULATION OF TOPOTECAN CONTAINING THE DRUG SUBSTANCE MANUFACTURED BY NEW PROCESS RELATIVE TO THE CURRENT STUDY FORMULATION OF TOPOTECAN IN PATIENTS WITH ADVANCED SOLID TUMORS
REFMAL32	AN OPEN-LABEL, SAFETY, PHARMACOKINETIC AND PHARMACODYNAMIC STUDY OF MULTIPLE DOSES OF GW572016 TO EXAMINE THE INHIBITION OF EGFR/ERBB-2 PHOSPHORYLATION IN CANCER PATIENTS WITH SOLID TUMORS
REFMAL33	A PHASE I TRIAL OF WEEKLY AMONAFIDE (AMF)IN PATIENTS WITH ADVANCED, SOLID TUMORS
REFMAL34	A PHASE I STUDY OF TOPOTECAN IN COMBINATION WITH DOCETAXEL IN PATIENTS WITH REFRACTORY AND/OR ADVANCED SOLID TUMORS
IBCSG24-02	(SOFT TRIAL) Suppression of Ovarian Function Trial (SOFT) A Phase III Trial Evaluating the Role of Ovarian Function Suppression and the Role of Exemestane Adjuvant Treatment for Pre-menopausal Women w/Endocrine Responsive Breast Cancer Tamoxifen Versus Ovarian Function Suppression + Tamoxifen Versus Ovarian Function Supression + Exemestane
S0622	Phase II studies of two different schedules of Dasatinib (NSC-732517) in bone metastasis predominant metastatic breast cancer.
CRN-004	A Phase II Trial of Neoadjuvant Docetaxel with Carboplatin and Capecitabine in Locally Advanced Her 2 Negative Breast Cancer.
TAS108-004	A Phase II, Randomized, Double-blinded Efficacy and Safety Study of Three Doses of TAS-108 Administered Orally in Postmenopausal Patients with Locally Advanced or Locally Recurrent Inoperable or Progressive Metastatic Breast Carcinoma Following Standard First Line Endocrine Therapy.
ALSSMBC0606	Phase 2 trial of Capecitabine in combination with fulvestrant for postmenopausal women with hormone receptor positive metastatic breast cancer.
20090301	A Phase 3, Multi-center, Open-Label, Randomized Study of Gemcitabine/Carboplatin, with or without BSI-201, in Patients with ER-, PR-, and HER2-Negative Metastatic Breast Cancer
N063D/ALT	Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation Study. A Randomised, Multi-Centre, Open-Label, Phase III Study of Adjuvant Lapatinib, Trastuzumab, Their Sequence and Their Combination in Patients with HER2/ErbB2 Positive Primary Breast Cancer
CZOL446E2352	CZOL446E2352 aka OPTIMIZE 2 A prospective, randomized, double-blind, stratified, placebo-controlled, multi-center, 3-arm trial of the continued efficacy and safety of Zometa (every 4 weeks vs. every 12 weeks vs. placebo) in patients with documented bone metastases from breast cancer.
07040	A Phase 2, Multi-center, Open-Label, Randomized Trial of Gemcitabine/Carboplatin, with or without BSI-201, in patients with ER, PR, and HER2-negative metastatic breast cancer
98-04	Phase III Trial of Observation Plus or Minus Tamoxifen VS. RT Plus or Minus Tamoxifen for Good Risk Duct Carcinoma In-Situ (DCIS) of the Female Breast.
BRE145	A Randomized Trial of IxempraTM vs. Taxol in Adjuvant Therapy of Triple-Negative Breast Cancer (TITAN)
USOncology09-008	A Phase 3, Multi-center, Open-Label, Randomized Trial of Gemcitabine/Carboplatin, with or without BSI-201, in patients with ER, PR, and HER2-negative metastatic breast cancer
INST0818	High-Speed MR Spectroscopic Imaging of Choline and Lipids in Breast Cancer
AVF4349n	An obsevational study of treatment patterens and safety outcomes for metastatic or locally recurrent breast cancer
B9E-US-S308(a)	A Phase II Randomized Trial of Gemcitabine Plus Paclitaxel and Gemcitabine Plus Docetaxel In Patients With Metastatic Cancer
USOncology08-217	A randomized phase III, double-blind, placebo-controlled multicenter trial of everolimus in combination with trastuzumab and paclitaxel, as first line therapy in women with HER2-positive locally advanced or metastatic breast cancer
NCCTGN04CA	Pilocarpine For Vaginal Dryness: A Phase III Randomized, Double Blind, Placebo-Controlled Study
S0226	Phase III Randomized Trial of Anastrozole vs Anastrozole and Fulvestrant as First Line Therapy for Post Menopausal Women with Metastatic Breast Cancer
RM45	An Ascending Single and Multiple Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HKI-272 Administered Orally to Subjects with HER2/new-Positive Tumors
RM44	A Phase Ib study of RAD001 in Combination with Gemcitabine, Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Patients with Advanced Solid Tumors
NSABPB-39	A Randomized Phase III Study of Conventional Whole Breast Irradiation (WBI) Versus Partial Breast Irradiation (PBI) for Women with Stage 0, I, or II Breast Cancer
USON06-090	Phase III Trial of Adjuvant TC versus TAC in HER2-Negative Early Stage Breast Cancer Patients
INST0716C	INST 0716C, Inflammatory Breast Cancer (IBC) Research Program, is now Open to Enrollment.
Astellas155-CL-036	Astellas 155-CL-036: A Phase II, Multicenter, Open-Label, Randomized Study of YM155 Plus Docetaxel in Subjects with HER2 Negative Metastatic Breast Cancer
9238IL/0048	A Randomized, Double Blind, Multicenter Study to Compare the Efficacy and Tolerability of Fulvestrant (FASLODEX) vs. Exemestane (AROMASIN) in Postmenopausal Women with Hormone Receptor Positive Advanced Breast Cancer with Disease Progression after Prior Non-Steroidal Aromatase Inhibitor (AI) Therapy
BRE60	Phase II Study of Thalidomide in Combination With Capecitabine In Patients With Metastatic Breast Cancer
USOR07119	A Multicenter Phase III Randomized Trial of Adjuvant Therapy for Patients with HER2-Positive Node-Positive or High Risk Node-Negative Breast Cancer Comparing Chemotherapy Plus Trastuzumab with Chemotherapy Plus Trastuzumab Plus Bevacizumab
XRP116248A/2001	A Multicenter Phase II Randomized Study Comparing RPR116258A administered as a 1-hour Intravenous Infusion Either Weekly (D1, D8, D15, D22 Every 5 weeks) or Every three Weeks Versus RPR109881A Administered as a 1-hour Intravenous Infusion Every Three Weeks in Taxoid Resistant Metastatic Breast Cancer Patients
INST0703C	GPR30 in Breast Cancer: A Correlative Study
USOR06090	Phase III Trial of Adjuvant TC versus TAC in Early Stage HER2-Negative Breast Cancer Patients.
06-030	Phase II Randomized Trial of Fulvestrant With or Without Dasatinib in Men and Postmenopausal Women who have Hormone Receptor-positive Advanced Breast Cancer Previously Treated with an Aromatase Inhibitor
INST0611C	DNA Decatenation of Breast Cancer by Metnase
DMS30203R	BNP7787 vs. Placebo for Prevention of Paclitaxel Neurotoxicity: A Double-Blind Multicenter Randomized Phase 3 Trial in Patients with Metastatic Breast Cancer